EMA Approves Astellas’ Xtandi for Non-Metastatic Hormone-Sensitive Prostate Cancer
The European Medicines Agency (EMA) has granted Japan-based Astellas (TYO: 4503) an indication extension approval...
FDA Accepts Takeda’s Filing for Subcutaneous Entyvio as Maintenance Therapy for Crohn’s Disease
The US Food and Drug Administration (FDA) has accepted a filing from Japan-based Takeda (TYO:...
AbbVie’s Skyrizi Outperforms Janssen’s Stelara in Phase III Crohn’s Disease Trial
AbbVie (NYSE: ABBV) has announced early data from a Phase III trial that compared the...
Boehringer Ingelheim Gets NMPA Approval for Brigimadlin Safety and Efficacy Study in China
Germany-based Boehringer Ingelheim (BI) has announced that it has received approval from the National Medical...
NHSA Unveils Measures to Enhance Smart Monitoring and Auditing of Basic Medical Insurance Funds
The National Healthcare Security Administration (NHSA) has released a notification detailing planned measures to improve...
MSD’s Sotatercept Demonstrates Positive Interim Results in Phase III PAH Studies
Merck, Sharp & Dohme (MSD; NYSE: MRK) has presented interim data from Phase III and...
Suzhou Porton Biologics Partners with BRL Medicine to Advance Gene and Cell Therapy Pipeline
China-based Contract Development and Manufacturing Organization (CDMO) Suzhou Porton Biologics Ltd has entered into a...
AstraZeneca’s Tagrisso Combination Therapy Shows Improved Efficacy in EGFR-mutated NSCLC
UK-headquartered AstraZeneca (AZ; NASDAQ: AZN) has announced interim Phase III data demonstrating that the addition...
Jiangsu Recbio and Yikang Biological Partner to Develop RSV Preventative Vaccine
Jiangsu Recbio Technology Co., Ltd, a China-based biotechnology company, has entered into a product development...
Janssen Reports Positive Results from Phase Ib/II Study of Rybrevant Combo in EGFR-mutated NSCLC
Johnson & Johnson (J&J; NYSE: JNJ) subsidiary Janssen has provided an update on an ongoing...
AstraZeneca’s Enhertu Shows Promising Results in Phase II HER2-mutant NSCLC Trial
AstraZeneca (AZ; NASDAQ: AZN) has released early data from a Phase II trial investigating the...
Innovent Biologics Plans Share Placement to Raise HKD 2.36 Billion for Global Expansion
China-based biotech Innovent Biologics Inc., (HKG: 1801) has issued a notice stating its intention to...
NMPA Pilots Priority Review for Rare Disease Formula Foods, Aims to Reduce Approval Time
The National Medical Products Administration (NMPA) has initiated a pilot program to implement “Priority review...
Huadong Medicine’s Subsidiary Viora Ltd’s V20 Accepted for NMPA Review
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that the National Medical Products Administration...
Gan & Lee Pharmaceuticals Initiates Phase II Clinical Study for Weekly Insulin GZR4
Gan & Lee Pharmaceuticals (SHA: 603087), a China-based pharmaceutical company, has announced the dosing of...
Grand Pharmaceutical Receives NMPA Approval for Generic Carbaglu for Hyperammonemia Treatment
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that it has received marketing approval...
JW Therapeutics and 2seventy Bio Expand Partnership for Cell Therapy Development
China-based cell therapy firm JW Therapeutics (HKG: 2126) and US biotech 2seventy Bio Inc., (NASDAQ:...
Wuhan YZY Biopharma Aims to Raise HKD 220 Million in Hong Kong IPO
Wuhan YZY Biopharma Co., Ltd, (HKG: 2496) a biopharmaceutical company specializing in targeted cancer drugs...
Exelixis Secures Global Rights to Develop Insilico Medicine’s USP1 Inhibitor ISM3091
China-based generative artificial intelligence (AI)-driven biotech Insilico Medicine has entered into an exclusive license agreement...
Burning Rock’s CanCatch MRD Product Shows Superiority in Postoperative NSCLC Monitoring
China-based medtech firm Burning Rock Ltd (NASDAQ: BNR) has revealed positive findings from a five-year...